Cartesian TherapeuticsRNAC
13F holders, Q2 2024 (June 30)3holders −63
1new positions
64sold out
$23.33avg. 13F price*
At the end of Q2 2024, 3 institutions reported holding Cartesian Therapeutics Inc. (RNAC) in their 13F filings, down 63 from Q1 2024. 1 opened new positions and 64 sold out. The largest holders were MetLife Investment Management, LLC ($11K), Osaic Holdings, Inc. ($31) and Cwm, LLC ($0).
- Company
- Cartesian Therapeutics Inc.
- CUSIP
- 816212104
- Latest filing quarter
- Q2 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $11K |
| Exits | 64 | $58.3M |
All 13F filers, Q1 2024 → Q2 2024: 413 shares bought and 54,667,827 shares sold, net −54,667,414 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| MetLife Investment Management, LLC | 0.00% | New | 410 | $11K |
| Osaic Holdings, Inc. | 0.00% | Reduce -99.1% | 62 | $31 |
| Cwm, LLC | 0.00% | Add +300.0% | 4 | $0 |
"% of holder's portfolio" is RNAC's weight in each manager's 13F, not the share of Cartesian Therapeutics Inc. the manager owns.